No significant change occurred in the uptake by the thyroid of male Wistar rats of a standard dose of carrier-free 131 1 administered intraperitoneally and its retention by the thyroid, as measured by biological and effective half-life, after feeding these rats a powdered pelleted diet containing lithium carbonate (I .
Introduction
Administration of lithium is known to cause various changes in thyroid functions such as goitre, decreased serum levels of thyroid hormones and elevation of serum thyrotropin (Schou 1976) . The effect of lithium on 131 1 uptake is described variously as stimulatory or inhibitory (Fyro et af. 1973; Mannisto et af. 1971) . Inhibition of thyroidal secretion has been postulated as a major effect of lithium (Sedvall et af. 1968; Berens et af. 1970; Dhawan et af. 1985) . The inhibitory effect of lithium on the rate of disappearance of radioiodine from the thyroid gland in hyperthyroid subjects has led to the use of lithium as an adjunct to 131 1 therapy for thyrotoxicosis (Burrow et af. 1971) . Turner et af. (1976) found that lowdosage lithium therapy increased the retention of a standard therapeutic dose of 131 1 in the thyroid gland. In this paper, we have further evaluated the effects of short-term and longterm lithium treatment on the uptake and retention of 131 1 in the rat thyroid.
Materials and Methods
Male Wistar rats of the Institute's colony, each weighing 140-160 g, were used in this study. They were held for at least a week in the Department's animal house prior to them being put on a diet containing lithium carbonate. The pellet diet supplied by Hindustan Levers was ground to powder. Lithium carbonate was adminstered in the diet (1·1 g per kg of diet) so as to give fairly constant levels of lithium in the serum (Bagchi et al. 1978) . The diet given to control groups was not supplemented with lithium. During the study, the animals had free access to water and diet. Lithium carbonate was administered for r day, 3 days, 5 days, 7 days, 10 days, 1 month, 2 months, 4 months and 6 months.
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The rats were injected with 1·48 MBq of 131 1 intraperitoneally. For the measurement of 1311 uptake in vivo, the animals were held above a suitably shielded Nal (Tl) crystal gamma-sensitive probe. Radioactivity in the neck area was measured at 2 h, 24 h and then daily for up to 10 days after the injection (see Leppaluoto et al. 1973) . Lithium administration in the diet continued until the uptake studies were completed. Blood samples were collected from rats under light ether anaesthesia by occulat vein puncture before and after the uptake studies, and serum was separated by centrifugation for the estimation of lithium levels using an EEL flame photometer, mark II (Brown and Legg 1970) .
To investigate the retention of 131 1 in the thyroid, the uptake studies were carried out for 10 days to find out the biological half-life of 1311. Percentage thyroidal 131 1 uptake was calculated by comparing the activity concentrated by the thyroid gland with that injected. The standard was also counted to account for the physical decay of the radioisotope and the possible instrumental errors or variations, if any, during the study. To estimate the biological half-life of 131 1, the percentage 131 1 uptake by the thyroid at various time intervals from 48 h onward was calculated by taking 48-h uptake as 100%. These values were then plotted on semi-log paper. Percentage thyroidal 13 II uptake was plotted onthe Y-axis (log-scale) and the time-interval on the X-axis (linear scale), and the biological half-life of 131 I was found by taking the difference on the X-axis of any two points where the percentage uptake is reduced by 50%. The effective half-life (Teff) was measured from the graph by taking thyroid counts at 48 h as 100%.
The dose of 131 1 delivered to the thyroid was calculated according to the following formula as used by Abdel-Nabi and Ortman (1983) . 
Results
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During the study the body weights of the rats rose steadily in both the control and lithium-treated groups. The serum lithium levels were high in the beginning and tended to be lower as the lithium treatment continued for a longer time (Table 1) .
No significant change was observed in 2 and 24 h uptake of 131 1 by the thyroid following lithium treatment for up to 7 days, when compared with controls (Table 2) . However lithium treatment for 10 days resulted in a decrease of 2 and 24 h 131 1 uptake by the thyroid when compared with the respective control group. Though uptake of 131 1 started to decrease after 7 days of lithium treatment, it was not statistically different from that of the control group at that time. The decrease in 2 and 24 h thyroidal 131 1 uptake was more marked after treatment with lithium for 1 month. The trend in decrease of uptake continued for up to 4 months of lithium treatment, but this decrease was less marked at 4 months than in the I-month group. The decrease in 24 h 131 I uptake was 49· 7% in the latter compared with a decrease of 19'5% in the group receiving lithium for 4 months. The data clearly show that the return to normal of 131 1 uptake in the lithium-treated group starts after 2 months of lithium treatment and by 6 months the difference between the control and the lithium-treated group becomes statistically insignificant. No significant change in T biol of 131 1 was observed up to 7 days of lithium treatment when compared with corresponding controls (Table 1) . However, after 10 days of lithium treatment there was a significant increase in Tbiol of 131 1 when compared with the controls, and this increasing trend continued for up to 6 months of lithium treatment. When T biol of 131 1 among different control groups was compared, a significant increase (P < 0'05) was observed in the 2-months control group when compared with the I-day control group. The values of Terr for 131 1 in all the lithium-treated groups showed a similar trend to that of the Tbiol values.
The product of Terr for 131 1 and 24 h thyroidal 131 1 uptake, together with the dose of 131 1 delivered to the thyroid in control and lithium-treated rats are shown in Table 3 .
The product of Terr and 24 h 131 1 uptake was observed to be significantly (P < 0'05, P < 0'01) low after 10 days and 1 month of lithium treatment; similarly, the doses of 131 1 delivered to the thyroid were found to be significantly (P < 0'05, P < 0'01) lower after 10 days and 1 month of lithium treatment. However, no change was observed in the product of Terr and 24 h uptake and the dose of 131 1 delivered to the thyroid after 2 and 
Discussion
The serum lithium levels obtained in this study were within the pharmacological range (Hullin and Johnson 1970) . The reduction in uptake of 131 1 in thyroid after short-term lithium treatment that was observed is in agreement with the earlier studies (Hullin and Johnson 1970; Leppaluoto et al. 1973) . In a similar study to ours Abuzzahab et al. (1969) noticed an increase in uptake of 131 I in ewes following lithium treatment (serum levels O· 8-1·0 mEq L -1) for 4 months and the uptake returned to normal levels after 7 months of lithium treatment. It is possible that this normalization trend in long-term lithium-treated animals is mediated through the thyroid stimulatory hormone (TSH) as postulated by Sedvall et al. (1968) , who indicated that the uptake of 131 1 may be regulated by TSH. When circulating levels of triiodothyronine (T3) and thyroxine (T4) are decreased following chronic lithium treatment, the consequent rise in TSH normalizes the thyroidal uptake of 1311. Thus, a lithium-induced inhibition of thyroxine secretion is overcome by compensatory hyperthyrotropinaemia.
In our study, a significant increase in the biological and effective half-life of 131 I taken up by the thyroid was observed after 10 days of lithium treatment and continued for up to 6 months. Earlier studies (Burrow et al. 1971; Spaulding et al. 1972) showed that the administration of lithium increased the retention of 131 1 in the thyroid gland. These observations were further confirmed by Turner et al. (1976) . The increase in the values of Tbiol and Terr were more or less the same in groups of rats treated with lithium for 2, 4 and 6 months. Any possible effect of age-induced increases in these values was allowed for by using control animals of similar ages except in the case of 1-and 3-day control groups in which the variation in body weights was negligible. An increase in Tbiol and Terr was observed in control groups 2, 4 and 6 months of age when compared with the I-day control group. This could be due to ageing; the mechanisms involved, however, are not clear.
Previous observations indicated that lithium inhibits the release of radioiodine from the thyroid, thereby prolonging the biological half-life of 131 1 (Sedvall et al. 1968; Berens et al. 1970; Spaulding et al. 1972; Turner et al. 1976) . Our increase in the thyroid biological half-life of 131 1 is in agreement with these findings. The increase may be due to an inhibitory effect of lithium on the disappearance of 131 1 from the thyroid.
In order to find out the retention of 131 1 in thyroid, we calculated the dose of 131 1 delivered to the thyroid. As the effective half-life of 131 1 in thyroid increases after lithium administration and the thyroidal 131 1 uptake reduces to within normal limits after 6 months of lithium treatment, the dose delivered to the thyroid, hence its retention, will be more, if rats are pretreated with lithium.
